Twitter bird sign sells for nearly $35,000 at auction
Tuberculosis cases in the US rose to their highest levels in more than a dozen years
Trump’s executive order to dismantle the Education Department was inspired by the Heritage Foundation’s decades-long disapproval of the agency
Panama reopens talks about the future of a controversial copper mine, but opposition remains
Andrew Tate en route to Romania to meet legal obligations pending trafficking probe
Serbia deputy prime minister says Russian spies help put down protests
New Yorkers scramble for free eggs
Kyan Evans and favored No. 12 seed Colorado State beat short-handed Memphis 78-70 in March Madness
Car show organized in Whitman, Massachusetts, for an 11-year-old boy battling cancer
(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.
The transaction is expected to close in the second quarter of 2025, it added.
(Reporting by Alban Kacher)
